HealthMore in Health→
Apitegromab Preserves Lean Mass During Tirzepatide Weight Loss in Phase 2 Trial
Key Takeaways
- Apitegromab reduced lean mass loss by 1.9 kg vs placebo (54.9% retention) during tirzepatide weight loss.
- Total weight loss was similar between groups, showing selective lean mass preservation.
- Adverse events were comparable: 76% apitegromab vs 71% placebo; SAEs 2% each.
- Proof-of-concept supports further development of myostatin inhibition with incretin therapies.
DE
DT Editorial Team··via nature.com
